Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines |
| |
Institution: | 1. Pathology, University of Cambridge, Cambridge, United Kingdom;2. Gynecologic Oncology, Medical University Vienna, Vienna, Austria;3. Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA;4. Late Stage Development Vaccines, Merck & Co., Inc., Kenilworth, NJ USA;5. Global Center for Scientific Affairs, Merck & Co., Inc., Kenilworth, NJ, USA;6. Global Vaccines Medical Affairs, Merck & Co., Inc., Kenilworth, NJ USA;7. Universidad del Rosario, Bogota, Colombia;8. Certara Evidence and Access, Montreal, Quebec, Canada;9. Medicine, Indiana University School of Medicine, Indianapolis, IN, USA |
| |
Abstract: | IntroductionStudies on the cross-protective effect of HPV bivalent and quadrivalent vaccines demonstrated inconsistent findings against additional HPV types covered by the nonavalent vaccine. The objective of this study was to conduct a systematic literature review to assess the consistency and durability of the cross-protective neutralizing antibody immune responses of the currently licensed bivalent and quadrivalent vaccines to non-vaccine HPV types targeted by the nonavalent vaccine (HPV 6, 11, 31, 33, 45, 52, and 58).MethodsPubMed and EMBASE databases were searched from 2008 to 2019 to identify studies reporting antibody/immune response after vaccination with either the bivalent, quadrivalent, or nonavalent vaccine. Key outcomes were seroconversion, seropositivity or geometric mean titers against HPV types 6, 11, 31, 33, 45, 52, and 58.ResultsEighteen publications met inclusion criteria, reporting on 14 interventional and five observational studies. Across all studies, immune responses to non-vaccine high-risk HPV types after bivalent vaccination were higher than baseline or quadrivalent vaccine. Nonavalent vaccine elicited near total seroconversion to HPV types 31, 33, 45, 52, and 58, with seropositivity remaining near 100% up to 24 months post-dose 1. In contrast, bivalent and quadrivalent vaccination resulted in lower seroconversion levels for non-vaccine types, which waned over time.ConclusionsThe cross-protection antibody/immune response among participants having received all three doses of bivalent or quadrivalent vaccine is not comparable to the specific response elicited by HPV vaccine types. Even in cases where a statistically significant cross-reactive immunological response is reported, long-term data on the duration of the response beyond two years are very limited. Further, the lack of a standard for assays limits comparability of results between studies. |
| |
Keywords: | Cross-protection HPV HPV vaccine Human papillomavirus Immune response Antibody response cLIA"} {"#name":"keyword" "$":{"id":"k0040"} "$$":[{"#name":"text" "_":"competitive Luminex immunoassay CVT"} {"#name":"keyword" "$":{"id":"k0050"} "$$":[{"#name":"text" "_":"Costa Rica Vaccine Trial ELISA"} {"#name":"keyword" "$":{"id":"k0060"} "$$":[{"#name":"text" "_":"enzyme-linked immunosorbent assay GMC"} {"#name":"keyword" "$":{"id":"k0070"} "$$":[{"#name":"text" "_":"geometric mean concentration GMT"} {"#name":"keyword" "$":{"id":"k0080"} "$$":[{"#name":"text" "_":"geometric mean titer GST-L1"} {"#name":"keyword" "$":{"id":"k0090"} "$$":[{"#name":"text" "_":"glutathione S-transferase (GST)-L1 multiplex serology assay HAVANA"} {"#name":"keyword" "$":{"id":"k0100"} "$$":[{"#name":"text" "_":"HPV Amongst Vaccinated and Non-vaccinated Adolescents HPV"} {"#name":"keyword" "$":{"id":"k0110"} "$$":[{"#name":"text" "_":"human papillomavirus IgA"} {"#name":"keyword" "$":{"id":"k0120"} "$$":[{"#name":"text" "_":"immunoglobulin A IgG"} {"#name":"keyword" "$":{"id":"k0130"} "$$":[{"#name":"text" "_":"immunoglobulin G MFI"} {"#name":"keyword" "$":{"id":"k0140"} "$$":[{"#name":"text" "_":"median fluorescence intensity PBNA"} {"#name":"keyword" "$":{"id":"k0150"} "$$":[{"#name":"text" "_":"pseudovirion-based neutralization assay RCT"} {"#name":"keyword" "$":{"id":"k0160"} "$$":[{"#name":"text" "_":"randomized controlled trial UK"} {"#name":"keyword" "$":{"id":"k0170"} "$$":[{"#name":"text" "_":"United Kingdom |
本文献已被 ScienceDirect 等数据库收录! |
|